Buy Like Buffett
Watchlist

NUTEX HEALTH INC.

NUTX · Technology · $1.0B mkt cap · FY2025 filings · Narrow moat ·

On the watchlist

Narrow moat
Share / Embed this score
Embed this score

The five investor questions

90

2021–2025 (latest 5 aligned FYs; v3 window cap 5): revenue $332M to $875M, increasing; diluted EPS 0.22 to 10.48, increasing. Latest-filed diluted EPS remains usable for Business Trend, but an integer share-count change lacks enough evidence to confirm a comparable EPS basis; valuation growth therefore stays at 0%.

40

Median gross margin 40.9% over 9y, variable.

83

Median ROIC 27.5%, above the 12% hurdle in 50% of years.

81

Net cash position — no leverage risk.

24

Owner earnings changed trend unclear over up to the ten most recent annual observations.

Price vs. value if growth stopped today

A cautious baseline, not a price target: what the shares may support if normalized owner earnings simply hold steady.

Above value if growth stopped todayBelow value if growth stopped today
35% above value if growth stopped today
$68.8M
$107.82
$107.82
$145.87
35% above value if growth stopped today

What today’s price assumes: owner earnings growing ~6%/yr over 5 years. The zero-growth estimate assumes owner earnings stay flat (0% growth).

How to read this

We solve for the constant annual change in owner earnings that would make the five-year zero-growth estimate equal today’s price. This keeps the existing model inputs and calculation unchanged; it is an expectations lens, not a forecast.

This zero-growth estimate assumes trailing owner earnings persist — unreliable for declining businesses. The recent FY revenue series does not trigger the three-consecutive-declines flag.

Among the current top-score group, the median current price is 239% above the zero-growth estimate across 48 of the current top 50 companies by Moat Score with both values.

Score records captured Jul 26, 2026.

Exactly which 50 companies?

FTNT, META, MEDP, IBEX, MSFT, GOOGL, LULU, ANF, IDXX, TXRH, FHI, QLYS, FFIV, ADBE, LLY, MANH, VEEV, GRMN, SSD, MNST, DOCS, MCO, CPRT, NTAP, LRCX, NVDA, CORT, SFM, MPTI, ULTA, SN, RMD, ROL, PAYC, IRMD, INTU, DECK, MORN, LGCY, DAL, GWW, ISRG, MPWR, CTAS, LOPE, MRK, CMG, FAST, BKNG, ORLY

Missing a usable price or zero-growth estimate: ANF, BKNG.

Model details under moat-index@3.0.0: zero-growth multiple 11.1×, capped-growth comparison at no more than 18×; 9% discount rate; high-end growth 0% (capped at 4%) using min(5y revenue CAGR, 5y diluted-EPS CAGR), clamped to 0%–4%; maintenance capex uses min(capex, D&A); abstain when D&A is unavailable. This is a disclosed model range, not intrinsic value as fact.

16 years of fundamentals

The business, in plain English

NUTEX HEALTH INC. booked $875M of revenue in FY2025 in the Technology sector and kept 50.8% of it as gross profit — a solid-margin business by that measure. After every other cost, 8.1% of each revenue dollar reached the bottom line.

Across the filed record, revenue grew from $874774 (FY2010) to $875M (FY2025) — about 58.5% a year compounded over 15 years.

It earned 109.0% on invested capital in the latest filed year, FY2025. Across the full 10-year measurable filed record, median ROIC was −40.6%. Over the v3 recent window (6 measurable filed years), median ROIC was 27.5%. The Returns on Capital filter above scores it 83/100.

The balance sheet carried $42.5M of total debt in FY2025 against $88.8M of owner earnings — roughly 0.5 years of owner earnings to retire it all. Balance-Sheet Safety scores it 81/100.

Put together: Business Trend is the strongest of the five filters (90/100) and Capital Allocation the weakest (24/100), which is how NUTX lands at 64/100 — a Narrow moat.

This breakdown is generated from the filed numbers and sub-scores above — no outside narrative, no estimates. Where a filing doesn’t disclose an input, the sentence that would need it is omitted instead of guessed.

FY2010–FY2025 · 16 fiscal years, normalized from NUTX’s SEC filings

Sales, as filed$875M FY2025
$0$500M2010201520202025
Revenue kept after cost of goods50.8% FY2025
0%100%2010201520202025
Standard ROIC or separately labeled Operating ROICROIC 109.0% FY2025

Not meaningful FY2018: invested capital is negative (cash exceeds debt + equity). Not meaningful FY2020: invested capital is negative (cash exceeds debt + equity)

−500%0%2010201520202025
Cash an owner could take out$88.8M FY2025
−$250M$02010201520202025

The explained ROIC gaps have filed inputs but no meaningful positive invested-capital denominator. Other gaps mean the item is not in the filings for that year. The series is never interpolated or estimated. The Table view lists every filed value, including operating and net margins, total debt, and share count.

Flagship explainer

How NUTEX HEALTH INC. makes its money

NUTEX HEALTH INC.'s filing does not supply enough comparable lines for a truthful flow chart — here's what is filed:

Table alternative
Filed lineValue% of revenueSource
$875M100%
$444M51%
$276M31%
Income before tax$245M28%
Income tax$64.4M7%
$70.8M8%
Source: · event Dec 31, 2025 · retrieved Jul 26, 2026 · annual-row source set

Flagship explainer

What NUTEX HEALTH INC. owns — and owes

NUTEX HEALTH INC.'s filing tags don't support a full breakdown — here's what is filed:

Table alternative
Filed lineValue% of assetsSource
Total assets$919M100%
Cash and equivalents$186M20%
$42.5M5%
Stockholders’ equity$329M36%
Source: · event Dec 31, 2025 · retrieved Jul 26, 2026 · annual-row source set

Flagship explainer

What drives NUTEX HEALTH INC.’s return on equity?

ROE is five filed business factors multiplied together.

DuPont return on equity factor treeReturn on equity branches into tax burden, interest burden, operating margin, asset turnover, and the equity multiplier.Return on equity31%Tax burden29%net income ÷ pretax incomeInterest burden89%pretax ÷ operating incomeOperating margin31%operating income ÷ revenueAsset turnover1.11×revenue ÷ average assetsEquity multiplier3.41×average assets ÷ average equityAs of 2025-12-31 · 1 SEC filing sourceBuy Like Buffett · buylikebuffett.com
DuPont source inputs
InputValueFiscal yearSource
$70.8MFY2025
Income before tax$245MFY2025
Operating income$276MFY2025
$875MFY2025
Ending assets$919MFY2025
Beginning assets$655MFY2024
$329MFY2025
$132MFY2024
Source:
  • SEC filingFiling detailsAccession 0001628280-26-015168
· event Dec 31, 2025 · retrieved Jul 26, 2026 · annual-row source set
Embed this chart

Flagship explainer

Where NUTEX HEALTH INC.'s cash went

NUTEX HEALTH INC.’s filing does not supply enough provenance-matched cash-flow lines for a truthful flow chart — here’s what is filed:

Table alternative
Filed lineValue% of cash from operationsSource
Cash from operations$248M100%
Depreciation and amortization$20.5M8%
Source: · event Dec 31, 2025 · retrieved Jul 26, 2026 · annual-row source set

Curated 19-manager tier

Who reported holding NUTEX HEALTH INC.

Delayed public 13F reports for 2026-Q1—not live positions, trades, or recommendations.

0 holding0 exited0 not holding0/19 resolved19 unavailable

Named manager positions and quarter-over-quarter changes
ManagerReported positionQuarter-over-quarterFiling accession
Abrams CapitalUnavailableComparison unavailableFiling unavailable
Akre CapitalUnavailableComparison unavailableFiling unavailable
Baupost GroupUnavailableComparison unavailableFiling unavailable
Berkshire HathawayUnavailableComparison unavailableFiling unavailable
Brave Warrior AdvisorsUnavailableComparison unavailableFiling unavailable
Dodge & CoxUnavailableComparison unavailableFiling unavailable
First EagleUnavailableComparison unavailableFiling unavailable
FundsmithUnavailableComparison unavailableFiling unavailable
Gardner Russo & QuinnUnavailableComparison unavailableFiling unavailable
Gates Foundation TrustUnavailableComparison unavailableFiling unavailable
Mairs & PowerUnavailableComparison unavailableFiling unavailable
Markel / Markel-GaynerUnavailableComparison unavailableFiling unavailable
Oakmark / Harris AssociatesUnavailableComparison unavailableFiling unavailable
Pershing SquareUnavailableComparison unavailableFiling unavailable
Polen CapitalUnavailableComparison unavailableFiling unavailable
Sequoia / Ruane CunniffUnavailableComparison unavailableFiling unavailable
Southeastern Asset ManagementUnavailableComparison unavailableFiling unavailable
Tweedy, BrowneUnavailableComparison unavailableFiling unavailable
Yacktman Asset ManagementUnavailableComparison unavailableFiling unavailable

Position size uses shares and filed value from each manager’s 13F. Portfolio weight uses the eligible long-share filing denominator. Changes compare only with the immediately preceding calendar quarter.

Source: Filing source unavailable · event Mar 31, 2026 · retrieved Jul 26, 2026

Flagship explainer

What NUTEX HEALTH INC. insiders reported

Records still being gathered — partial as of retrieval Aug 12, 2026.

Partial coverage: the incomplete Form 4 walk cannot establish no activity, an activity date, or zero counts.

Moat Score history

16 logged readings since Jul 17, 2026 · append-only, never rewritten

Moat Score over timeLast scored reading of each day, on the 0–100 scale63.6 / 100
0406080100WideNarrowShallowNo moatJul 17, 2026Jul 26, 2026

Breaks in the line mark methodology or normalizer upgrades — readings across versions aren’t compared, so a level shift there isn’t a change in the business.

Tier changesSame-methodology and same-normalizer crossings of the Wide / Narrow / Shallow bars

  1. Normalizer upgraded unstamped (version unknown)moat-xbrl-normalizer@1.1.0 — readings across versions aren’t comparedJul 26, 2026
  2. Methodology upgraded moat-index@2.0.0moat-index@3.0.0 — readings across versions aren’t comparedJul 23, 2026
  3. Methodology upgraded moat-index@1.2.0moat-index@2.0.0 — readings across versions aren’t comparedJul 20, 2026

Scores are logged append-only and never overwritten — this record cannot be reconstructed retroactively, which is exactly why it’s worth keeping.

Insider activity

Form 4 reports mix P/S market or private transactions with compensation-plan mechanics. Activity casually described as “insider selling” can include compensation mechanics; awards, tax withholding, and option exercises are shown by their exact filed class here, never collapsed into “Bought” or “Sold.”

These are disclosed filing facts and arithmetic aggregates, not a signal or verdict.

This machine-readable surface covers SEC ownership filings from 2003; it does not represent earlier paper-era records.

Records still being gathered — partial as of retrieval Aug 12, 2026.

Among the rows shown, A/F/M acquisition, payment or withholding, and exercise or conversion rows outnumber S sale rows (4 versus 0). The filing codes alone do not establish that every such row arose from a compensation plan.

Trailing-12-month totals and the 90-day cluster result are withheld because this issuer walk is incomplete.

InsiderShares owned afterDateFiling detail
Jaumot Frank EDirectorExercise or conversion of derivative security (M)Table I · Acquired · Common Stock603—Exercise or conversion of derivative security (M)—753Jul 31, 2026
1 filed lot
  • Table I · Common Stock: 603 shares at — (Exercise or conversion of derivative security (M)) · code M · owned after 753 ·
Grenas Cheryl YvonneDirectorExercise or conversion of derivative security (M)Table I · Acquired · Common Stock603—Exercise or conversion of derivative security (M)—670Jul 31, 2026
1 filed lot
  • Table I · Common Stock: 603 shares at — (Exercise or conversion of derivative security (M)) · code M · owned after 670 ·
Saunders Scott JDirectorExercise or conversion of derivative security (M)Table I · Acquired · Common Stock603—Exercise or conversion of derivative security (M)—603Jul 31, 2026
1 filed lot
  • Table I · Common Stock: 603 shares at — (Exercise or conversion of derivative security (M)) · code M · owned after 603 ·
Reed Michael LeeDirectorExercise or conversion of derivative security (M)Table I · Acquired · Common Stock603—Exercise or conversion of derivative security (M)—670Jul 31, 2026
1 filed lot
  • Table I · Common Stock: 603 shares at — (Exercise or conversion of derivative security (M)) · code M · owned after 670 ·

Source-event as of . Retrieved .

Track record

How NUTEX HEALTH INC.’s moat rated in each of the years we can reconstruct from its filings — scored only on what was knowable at the time — and what its price and returns did afterward. The score never saw a price; the two are joined only in hindsight, for education, not as a signal.

Point-in-time scores 2011–2025, one methodology version · reconstructed from filings on file each Dec 31 — never with hindsight

Point-in-time Moat Score (dot colored by tier)Indexed price (total-return (dividends reinvested))Rated Wide-moat that year

How to read this: each dot is what the engine would have scored NUTX on that December 31; the line below is its total-return price path (dividends reinvested) in the years since.

0406080100WideNarrowShallowNo moatPoint-in-time Moat Score125102050100200Indexed price · log scale (2016 = 100)201120142017202020232026

Two tracks, one timeline: the score has its own 0–100 scale (top), the price its own 100-based scale (bottom) — never a shared axis. The price path is a total-return (dividends reinvested) index built from the same data the forward returns use; gaps in the score line are years with no reconstructed rating (see the table for why). The Table view carries every value.

What followed, in the years it rated Wide

In the reconstructed history shown, NUTX did not rate Wide-moat in any year, so there is no wide-moat track record to report. That absence is itself the honest answer — we don’t manufacture a comparison where the rating never earned one.

Technology context

#165 of 744 scored Technology companies, ranked by Moat Score.

Nearest peers by Moat Score

  1. #163SWKS SKYWORKS SOLUTIONS, INC.63.8Narrow moat
  2. #164NRDS NerdWallet, Inc.63.7Narrow moat
  3. #166FCCN Spectral Capital Corporation63.5Narrow moat
  4. #167RHI Robert Half Inc.63.4Narrow moat

Compare NUTX with its nearest peers →All Technology companies on the Index →

Common questions about NUTX

Does NUTEX HEALTH INC. have an economic moat?
Based on its FY2025 SEC filings, the Moat Index scores NUTEX HEALTH INC. (NUTX) 63.6 out of 100 — a Narrow moat. The five questions behind that score begin at 20% each; if exactly one genuinely lacks data, the other four weights are renormalized and disclosed. revenue and EPS trend 90, pricing power 40, returns on capital 83, balance-sheet safety 81, capital allocation 24.
Is NUTX trading below the conservative owner-earnings estimate?
The value if growth stopped today — a zero-growth baseline — is $107.82 per share. It capitalizes normalized owner earnings at a 9% rate and assumes 0% growth. Versus a recent price of $145.87, that is 35% above value if growth stopped today. The model also publishes a capped-growth comparison, but the zero-growth estimate is the cautious baseline. It assumes trailing owner earnings persist and is unreliable for declining businesses. This is an educational estimate from primary SEC filings, not intrinsic value as a fact or investment advice.
How has NUTX's Moat Score changed over time?
The record logs 16 readings since Jul 17, 2026; the latest reads 63.6 out of 100 (narrow moat). No tier changes on record yet. (Methodology or normalizer upgrades on Jul 20, 2026, Jul 23, 2026, Jul 26, 2026 re-based the score; readings across versions aren't compared.) The history is append-only — readings are only ever added, never rewritten.

Scored from primary SEC filings via the public methodology. Educational only — not a recommendation to buy or sell NUTX. See the disclaimer.